PR Newswire·Oct 16, 2026, 8:30 AM ET

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

ATNM

Actinium Pharmaceuticals presented preclinical data on ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna from October 17–21, 2026.
An oral presentation highlighted ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings to support mutation-agnostic development.
Colorectal cancer data demonstrated ATNM-400 monotherapy activity in SW620 xenografts and enhanced responses when combined with bevacizumab plus oxaliplatin in HCT15 xenografts.
Ovarian cancer data showed durable antitumor activity for ATNM-400 monotherapy, including in bevacizumab-refractory tumors.
Findings collectively support ATNM-400 as a differentiated targeted radiotherapy for multiple solid tumors as both a standalone therapy & a combination partner with existing treatments.
ATNM-400 is a first-in-class Actinium-225 radioconjugate targeting a novel antigen distinct from PSMA.
The company is expanding its pipeline beyond metastatic castration-resistant prostate cancer (mCRPC) to include NSCLC, colorectal cancer, & ovarian cancer indications.
Sandesh Seth, Chairman & CEO, stated the data supports a strategy to address large patient populations across major solid tumor indications regardless of oncogenic mutation.
Presentation details include an oral session on Monday, October 19, 2026, & two e-posters covering NSCLC, colorectal, & ovarian cancer models.
Actinium holds approximately 250 patents & patent applications, including intellectual property related to cyclotron-based production of Ac-225.